Latest Posts
Knopp Biosciences LLC Provides Update on Areteia Therapeutics Dexpramipexole Program
Knopp Biosciences LLC reported today that Areteia Therapeutics Inc. announced the completion of a $75 million expansion of its Series A funding. The additional funds will be used to expand three ongoing Phase III clinical trials for dexpramipexole in the treatment of eosinophilic asthma. The financing was led by Bain Capital Life Sciences.
Knopp Biosciences LLC Provides Update on Biohaven Ltd. Kv7 Program
PITTSBURGH, PA, JANUARY 10, 2023 – Knopp Biosciences LLC (“Knopp”) reported today that Biohaven Ltd. (“Biohaven”) reported topline data on its initial Phase I study for BHVN 7000, an ion channel Kv7 activator to treat focal epilepsy. The preliminary results were...
Knopp Biosciences LLC Board of Managers Approves a $101 Millions Cash Distribution to Members
PITTSBURGH, PA, OCTOBER 4, 2022 – Knopp Biosciences LLC (“Knopp”) announced today that its Board of Managers approved a cash distribution of $101,000,834 to owners of record on October 14, 2022. The distribution will be made as proscribed by “waterfall” in Knopp’s...
Knopp Biosciences LLC Receives First Regulatory Milestone Payment From Biohaven Pharmaceutical Holding Company Ltd.
PITTSBURGH, PA, AUGUST 29, 2022 – Knopp Biosciences LLC (“Knopp”) announced today that it had received a $25 million regulatory milestone payment from Biohaven Pharmaceuticals Holding Company Ltd. (“Biohaven”) due to the filing of an IND application for BHVN-7000, a...
Knopp Biosciences LLC Provides Update on Biohaven Ltd. Kv7 Program
PITTSBURGH, PA, JANUARY 10, 2023 – Knopp Biosciences LLC (“Knopp”) reported today that Biohaven Ltd. (“Biohaven”) reported topline data on its initial Phase I study for BHVN 7000, an ion channel Kv7 activator to treat focal epilepsy. The preliminary results were...
Knopp Biosciences LLC Board of Managers Approves a $101 Millions Cash Distribution to Members
PITTSBURGH, PA, OCTOBER 4, 2022 – Knopp Biosciences LLC (“Knopp”) announced today that its Board of Managers approved a cash distribution of $101,000,834 to owners of record on October 14, 2022. The distribution will be made as proscribed by “waterfall” in Knopp’s...
Knopp Biosciences LLC Receives First Regulatory Milestone Payment From Biohaven Pharmaceutical Holding Company Ltd.
PITTSBURGH, PA, AUGUST 29, 2022 – Knopp Biosciences LLC (“Knopp”) announced today that it had received a $25 million regulatory milestone payment from Biohaven Pharmaceuticals Holding Company Ltd. (“Biohaven”) due to the filing of an IND application for BHVN-7000, a...
All Knopp News
Knopp Biosciences LLC Provides Update on Biohaven Ltd. Kv7 Program
PITTSBURGH, PA, JANUARY 10, 2023 – Knopp Biosciences LLC (“Knopp”) reported today that Biohaven Ltd. (“Biohaven”) reported topline data on its initial Phase I study for BHVN 7000, an ion channel Kv7 activator to treat focal epilepsy. The preliminary results were...
Knopp Biosciences LLC Board of Managers Approves a $101 Millions Cash Distribution to Members
PITTSBURGH, PA, OCTOBER 4, 2022 – Knopp Biosciences LLC (“Knopp”) announced today that its Board of Managers approved a cash distribution of $101,000,834 to owners of record on October 14, 2022. The distribution will be made as proscribed by “waterfall” in Knopp’s...
Knopp Biosciences LLC Receives First Regulatory Milestone Payment From Biohaven Pharmaceutical Holding Company Ltd.
PITTSBURGH, PA, AUGUST 29, 2022 – Knopp Biosciences LLC (“Knopp”) announced today that it had received a $25 million regulatory milestone payment from Biohaven Pharmaceuticals Holding Company Ltd. (“Biohaven”) due to the filing of an IND application for BHVN-7000, a...
Knopp Biosciences LLC Spins Off Dexparamipxole Platform to New Partnership With Population Health Partners and Investor Group Led By Bain Capital Life Sciences
PITTSBURGH, PA JULY 12, 2022 – Knopp Biosciences LLC (“Knopp”) announced today that it has spun off its dexpramipexole platform, a first-in-class oral therapy for eosinophilic asthma to Areteia Therapeutics, Inc. (“Areteia”). Areteia was created by Knopp and...
Biohaven Pharmaceutical Holding Company Ltd. Completes the Acquisition of Knopp Biosciences Ltd. Subsidiary Channel Biosciences LLC
PITTSBURGH, PA, APRIL 4, 2022 – Knopp Biosciences LLC (“Knopp”) announced today that the previously announced acquisition of Knopp’s wholly owned subsidiary Channel Biosciences LLC by Biohaven Pharmaceuticals Holding Company Ltd. (“Biohaven”) closed as of April 1,...
Biohaven Pharmaceutical Holding Company Ltd. to Acquire Channel Bioscience LLC Subsidiary of Knopp Biosciences LLC
NEW HAVEN, CT and PITTSBURGH, PA -- Feb. 25, 2022 -- Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven") and Knopp Biosciences LLC (“Knopp”) announced today that they have entered into a definitive agreement for Biohaven to acquire Channel Biosciences, LLC, a...
Knopp Biosciences Announces Positive Top-Line Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma
Primary endpoint was achieved, with dexpramipexole demonstrating a statistically significant reduction in blood eosinophil count over 12 weeks Reduction in blood eosinophil count correlated with clinically important improvement in lung function PITTSBURGH, PA, JANUARY...
Dexpramipexole Targets Eosinophilic Inflammation
Knopp Biosciences’ investigational, first-in-class drug, dexpramipexole, holds promise for patients with asthma and eosinophil-associated diseases. Asthma affects more than 300 million people worldwide, and is the most common noncommunicable disease among children. No...
Knopp Biosciences Completes Class C Financing and Elects David Adair to Board of Managers
PITTSBURGH, PA, NOVEMBER 11, 2020—Knopp Biosciences LLC today announced that it had completed a Class C equity financing of approximately $14 million led by Solas BioVentures, whose managing director, C. David Adair, M.D., was elected to the Knopp Board of Managers....
Knopp Biosciences NIH-funded Pain Program Advances to Second Year of HEAL Award to Discover Non-Opioid Treatments for Chronic Pain
PITTSBURGH, PA, OCTOBER 8, 2020—Knopp Biosciences LLC today announced that it entered the second year of research funded by the National Institutes of Health (NIH) to utilize its Kv7 platform to discover and develop non-opioid therapies for the treatment of chronic...
Knopp Biosciences Completes Enrollment in Phase 2 Trial of Oral Dexpramipexole in Eosinophilic Asthma
PITTSBURGH, PA, USA – September 16, 2020 – Knopp Biosciences LLC today announced the completion of enrollment in a Phase 2 trial of the oral small-molecule dexpramipexole in patients with moderate-to-severe eosinophilic asthma. The multi-center Phase 2 trial is a...
Knopp Biosciences to Present at Oppenheimer’s Private Life Sciences Company Call Series Aug. 18
PITTSBURGH, PA, USA – August 17, 2020 – Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet needs, announced the company’s...
Knopp Biosciences Receives Rare Pediatric Disease Designation for Kv7 Activator KB-3061 for Treatment of KCNQ2 Epileptic Encephalopathy
PITTSBURGH, PA– July 15, 2020 – Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet needs, announced today that it has received Rare...
Knopp Biosciences Appoints Stephen E. Butts to Board of Managers
PITTSBURGH, PA, USA – July 8, 2020 – Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet needs, announced the appointment of Stephen E....
KB-3061 Is a Potent Activator of Wild Type KCNQ Channels and Restores Current to KCNQ2 Encephalopathy Variants In Vitro
BACKGROUND Heterozygous KCNQ2 de novo variants (DNVS) are a cause of neonatal-onset developmental and epileptic encephalopathy (Q2-DEE). Most Q2-DEE variants are missense, and are clustered in hotspots that are domains for key protein functions, namely voltage...
Discovery and characterization of KB3061: A potent Kv7.2/7.3 ion channel activator for the treatment of KCNQ2 epileptic encephalopathy
Highlights Dominant-negative mutations in KCNQ2 cause epileptic encephalopathies (KCNQ2-EE) The Kv7.2/7.3 channel activator ezogabine (EZO) reduced seizures and may improve neurodevelopment in infants with KCNQ2-EE (Millichap et al., Neurol Genet, 2016) but was...
Knopp Biosciences Presents Data Further Characterizing Its Lead Kv7.2 Activator Drug Candidate For The Treatment Of Kcnq2 Epileptic Encephalopathy At The AES 2019 Annual Meeting
Preclinical data support the development of KB-3061 as a potential precision medicine treatment for a rare pediatric epilepsy PITTSBURGH, PA – December 9, 2019 – Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering...
Knopp Biosciences Appoints Mark Kreston as Chief Commercial Officer
30-year Industry Veteran Will Lead Knopp’s Global Commercialization, Business Development Functions as Company Advances Lead Asset into Late Stage Clinical Development PITTSBURGH, PA, USA—Knopp Biosciences LLC, a privately held drug discovery and development company...
Knopp Biosciences and University of Leicester Announce Update on Planned Phase 2 Clinical Trial of Oral Dexpramipexole in Severe Eosinophilic Asthma
Novel, oral eosinophil-depleting drug to be tested as a “pre-biologic” alternative treatment for reducing asthma exacerbations Trial enrollment scheduled to begin in 1H 2020 at severe asthma centers across the United Kingdom PITTSBURGH, PA, USA – December 2, 2019 –...
Knopp Biosciences to Present Data Characterizing Its Potassium Channel Activator Candidate for the Treatment of KCNQ2 Epileptic Encephalopathy at the American Epilepsy Society’s 2019 Annual Meeting
Presentations will detail lead molecule KB-3061 as a potential precision medicine treatment for a rare pediatric epilepsy PITTSBURGH, PA – November 27, 2019 – Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering...
Knopp Biosciences Receives NIH HEAL Grant to Discover and Advance Non-Opioid Treatment for Chronic Pain
Company to receive up to $8 million for its Kv7 platform as part of federal program to apply scientific solutions to reverse the national opioid crisis. PITTSBURGH, PA, SEPTEMBER 26, 2019—Knopp Biosciences LLC today announced that the National Institutes of Health...
Knopp Biosciences Receives Year 4 Renewal of NIH Blueprint Grant Award for Advancing the Kv7 Activator KB-3061 in a Rare Neonatal Epilepsy
Knopp’s lead Kv7 platform candidate advancing toward clinical studies in KCNQ2 epileptic encephalopathy PITTSBURGH, PA, SEPTEMBER 25, 2019—Knopp Biosciences LLC today announced the renewal of its grant award for Year 4 from the National Institutes of Health Blueprint...
Kv7.2/7.3 Activators as Precision Medicines for the Treatment of KCNQ2-EE
Ezogabine history and limitations Approved in 2011 as add-on therapy for partial adult onset seizures GSK voluntarily withdrew from the market in 2017 Photochemically unstable Dose-dependent side effects important benefits Patients with KCNQ2-NEE may benefit from...
Knopp Biosciences Reports Data Demonstrating Restoration of Function by KB-3061 in Cellular Model of Gene Variants Causing KCNQ2 Epileptic Encephalopathy
Knopp is advancing lead Kv7 platform candidate toward clinical studies in a rare pediatric epilepsy PITTSBURGH, PA – September 17, 2019 – Knopp Biosciences LLC today reported the results of preclinical experiments demonstrating that KB-3061, the lead molecule in the...
American Society of Hematology: “Dexpramipexole: a new antieosinophil drug?”
Gerald J. Gleich | University of Utah School of Medicine In this issue of Blood, Panch et al report that dexpramipexole reduces blood and tissue eosinophils and enables glucocorticoid reduction or cessation in patients with the hypereosinophilic syndromes(HESs).1...
The re-emergence of Kv7 drug discovery
Goals of the Knopp Kv7.2/7.3 activator program Discover and develop best-in-class Kv7.2/7.3 activators Capitalize on opportunities for improvement over ezogabine Eliminate chemical instability we hypothesize led to black box warning Avoid anilines in scaffold Improve...
Knopp Biosciences to Present Data Characterizing its Kv7 Technology Platform’s Potential for Delivering Precision Medicines to Treat Diverse Neurological and Smooth Muscle Diseases
Company’s lead Kv7 modulator, KB-3061, in preclinical development for KCNQ2 epileptic encephalopathy PITTSBURGH, PA, USA – September 13, 2019 – Knopp Biosciences LLC today reports data demonstrating that compound subgroups from its proprietary library of...
Developing Dexpramipexole for the Treatment of Eosinophilic Disorders
Dexpramipexole (DexP): A small molecule eosinophil-lowering drug A product of serendipity x2 “Non-dopaminergic” enantiomer of the Parkinson’s treatment pramipexole Originally developed in amyotrophic lateral sclerosis Low dopamine receptor potency versus pramipexole...
Dexpramipexole Responsiveness is Increased in Eosinophilic Subjects
INTRODUCTION Dexpramipexole is an oral investigational drug serendipitously noted to lower blood eosinophils during prior clinical trials in amyotrophic lateral sclerosis (ALS). In a subsequent trial in subjects with eosinophilic chronic rhinosinusitis and nasal...
Knopp Biosciences to Present Clinical Data for Dexpramipexole at 11th Biennial Symposium of the International Eosinophil Society
Dexpramipexole demonstrated significant reduction of eosinophil levels in blood and inflamed tissues PITTSBURGH, PA – July 9, 2019 – Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for...
Targeting Kv7.2/7.3 Activators for the Treatment of KCNQ2-NEE
Ezogabine history and limitations Approved in 2011 as add-on therapy for partial adult onset seizures GSK voluntarily withdrew from the market in 2017 Photochemically unstable Dose-dependent side effects important benefits Patients with KCNQ2-NEE may benefit from...
Knopp Biosciences Presents Positive Preclinical Data for Lead Neonatal Epilepsy Drug Candidate at 2019 Antiepileptic Drug and Device Trials XV Conference
Company’s lead molecule shows significant seizure protection in an animal model of epilepsy PITTSBURGH, PA – May 24, 2019 – Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory...
Knopp Biosciences to Present Data on its Potassium Channel Activator Program at 2019 Antiepileptic Drug and Device Trials XV Conference
Company’s Kv7 program targets epilepsy and other neurological conditions PITTSBURGH, PA – May 15, 2019 – Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological...
Knopp Biosciences Receives FDA Orphan Drug Designation for Dexpramipexole for Treatment of Hypereosinophilic Syndrome
PITTSBURGH, PA, USA – April 24, 2019 – Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet needs, announced today that the U.S. Food and...
Knopp Biosciences Enters Collaboration with Leading UK Investigators to Commence Phase 2 Clinical Trial of Dexpramipexole in Severe Eosinophilic Asthma
Lead investigator Prof. Salman Siddiqui sees potential to provide an alternative to oral steroids or biologic injections for severe asthma patients with high eosinophil counts PITTSBURGH, PA – Knopp Biosciences LLC, a privately held drug discovery and development...
CEO Dr. Michael Bozik’s interview with “The Heartbeat of Main Street” with Bank of America and ForbesBooks
Knopp Biosciences’ CEO Dr. Michael Bozik spoke with Gregg Stebben of ForbesBooks during the BIO CEO & Investor Conference regarding Knopp’s clinical-stage small molecule dexpramipexole and our science focused in neurological and immunological diseases with unmet...
Knopp Biosciences’ Rachel Kopper Elected National President of Women In Bio
PITTSBURGH, PA – Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with a high unmet need, today announced that Rachel L. Kopper, the company’s...
Knopp Biosciences Expands Research Collaboration with Cincinnati Children’s to Characterize Effect of Dexpramipexole in Inflammatory Diseases
Dr. Patricia Fulkerson, an authority in eosinophil biology, will analyze effects of dexpramipexole in stem cell culture system PITTSBURGH, PA — Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments...
Knopp Biosciences Expands Research Collaboration with Cincinnati Children’s to Characterize Effect of Dexpramipexole in Inflammatory Diseases
Dr. Patricia Fulkerson, an authority in eosinophil biology, will analyze effects of dexpramipexole in stem cell culture system PITTSBURGH, PA — Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments...
Knopp Biosciences Enters Research Collaboration with Baylor College of Medicine to Develop New Treatments for KCNQ2 Neonatal Encephalopathy
Dr. Ed Cooper, pioneering investigator of serious genetic epilepsies, will evaluate potential drug candidates using Knopp’s library of Kv7.2/7.3 channel activators PITTSBURGH, PA – Knopp Biosciences LLC, a privately held drug discovery and development company focused...
Editorial Accompanying Blood Cover Story Features Promise Of Dexpramipexole In Eosinophil-Associated Diseases
We’re in touch to share an editorial published in the current edition of the journal Blood concerning our lead drug candidate. Entitled “Dexpramipexole: a new antieosinophil drug?,” the editorial summarizes recent Phase 2 studies of dexpramipexole in...
Knopp Biosciences Announces Year 3 Renewal Of NIH Blueprint Grant Award For Advancing KCNQ2 Activators In Rare Neonatal Epilepsy
PITTSBURGH, PA, USA, SEPTEMBER 5, 2018—Knopp Biosciences LLC today announced the renewal of its grant award for Year 3 from the National Institutes of Health Blueprint Neurotherapeutics Network (BPN) to advance novel treatments for epilepsy. Based on milestone...
NIAID Now: Repurposed Drug Shows Promise for Treating Rare Eosinophilic Diseases
Eosinophils normally comprise a small portion of the body’s white blood cell population and help mediate inflammation and fight parasitic infections. Elevated levels of these cells can lead to serious health problems, including hypereosinophilic syndromes (HES)—rare,...
Knopp Biosciences Announces Publication of Phase 2 Trial Results of Dexpramipexole in Hypereosinophilic Syndromes (HES) in Blood
PITTSBURGH, PA, USA, MAY 10, 2018—Knopp Biosciences LLC today announced the publication of a report in the journal Blood that a Phase 2 study of dexpramipexole in hypereosinophilic syndromes (HES) met its co-primary endpoints. A team of investigators led by Dr. Amy...
American Society of Hematology: “Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes”
CLINICAL TRIALS AND OBSERVATIONS Hypereosinophilic syndromes (HESs) are a heterogeneous group of disorders characterized by peripheral eosinophilia and eosinophil-related end organ damage. Whereas most patients respond to glucocorticoid (GC) therapy, high doses are...
The Laryngoscope: “Dexpramipexole Depletes Blood and Tissue Eosinophils in Nasal Polyps With No Change in Polyp Size”
Objective Chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilia is a disease of the upper respiratory tract for which few therapies are available. Because the oral investigational drug dexpramipexole serendipitously decreased blood eosinophils in...
Knopp Biosciences Announces Renewal of NIH Blueprint Grant Award for Advancing KCNQ2 Modulators in Epilepsy
PITTSBURGH, PA, USA, OCTOBER 23, 2017—Knopp Biosciences LLC today announced the renewal and expansion of its grant award from the National Institutes of Health Blueprint Neurotherapeutics Network to advance novel treatments for epilepsy. The Phase 2 award under the...
Knopp Biosciences and APFED Announce Partnership to Advance Awareness of Hypereosinophilic Syndromes
PITTSBURGH, PA, and ATLANTA, GA, September 6, 2017—Knopp Biosciences LLC and the American Partnership for Eosinophilic Disorders (APFED) today announced a partnership to advance awareness of hypereosinophilic syndromes (HES) and to investigate the challenges facing...
Elsevier: “The targeted eosinophil-lowering effects of dexpramipexole in clinical studies”
Abstract Dexpramipexole, an orally bioavailable small molecule previously under clinical development in amyotrophic lateral sclerosis, was observed during routine safety hematology monitoring to demonstrate pronounced, dose- and time-dependent eosinophil-lowering...